What does the draft May reimbursement list change?

APTIC MARKET

According to the draft announcement, 19 packages of medicines, special dietary supplements and medical devices will be withdrawn from pharmacy reimbursement, and 12 others will be included. Funding will be given to 1 combination of active substances:

• Telmisartanum+Indapamidum - Ylpio product from PRO.MED.CS Praha a.s. (date of first marketing authorization: August 30, 2021) in all registered indications as of the date of the decision.

At the same time, according to the draft notice, no active substance will lose funding.

The draft does not provide for an expansion or narrowing of the scope of financing for active substances already on the reimbursement list,

According to the draft announcement, the first equivalent under 1 active substance will be introduced under pharmacy reimbursement:

• Eliminationmilk replac er diet - within group 217.6, Elimination milk replacer diet - elemental mix for infants and children, the product Blemil plus Elemental from Laboratorios Ordesa Sl with a reduction in the official selling price of -27% compared to the price of the only product reimbursed to date (the product Nutramigen PURAMINO from Mead Johnson & Company, LLC).

The level of the patient's co-payment will decrease for 309 packages of medicines, special foodstuffs and medical devices. Changes exceeding PLN 10 will apply to 7 of them. The largest reductions will apply to the following products: Firazyr(Icatibantum, solution for injection, 10 mg/ml, 1 amp.shots, 3 ml each) - by PLN 196.80, Toujeo(Insulinumglarginum, solution for injection in an injector, 300 IU/ml, 10 SoloStar injectors, 1.5 ml each) - by PLN 41.31, and Abasaglar(Insulinumglarginum, solution for injection in a cartridge, 100 IU/ml, 10 cartridges, 3 ml each) - by PLN 27.54. In the case of Firazyr, the reduction is due to a reduction in the official sales price of this drug, while the

For Toujeo and Abasaglar products, the reductions are due to changes in the basis of the limit in group 14.3, Pancreatic hormones - long-acting insulin analogs. As of May 2023, the limit in this group will be set by the product Abasaglar(Insulinumglarginum, solution for injection in a cartridge, 100 IU/mL, 10 cartridges of 3 mL).

In turn, the increase in patient surcharges will affect 325 packages. For 32 of them, the price increase will exceed PLN 10. The largest increases will apply to the following products: Novo-Helisen Depot(housedustmiteallergenextracts, concentration 3 - 5000 TU/ml or 5000 PNU/ml, 2 vials. 4.5 ml each) - by 452.70 zł, Icatibant Accord(Icatibantum, solution for injection, 10 mg/ml, 1 amp.shots, 3 ml each) - by PLN 152.47, and Trevicta(Paliperidonum...